• Acute leukemia/lymphoma:

  • Primary drugs:

    • Induction:

      • vincristine plus prednisone

    •  Remission maintenance (combination of drugs below):

      • mercaptopurine (Purinethol)

      • methotrexate

      • cyclophosphamide (Cytoxan)

  • Other useful drugs/modalities:

    •  asparaginase (El-spar)

    • daunorubicin (DaunoXome)

    • carmustine (BNCU,BiCNU)

    • cytarabine (ARA-C)

    •  allopurinol (Zyloprim, Purinol)-- supportive agent; xanthine oxidase inhibitor (reduces hyperuricemia)

    • spinal radiotherapy

• Hodgkin's Disease: (stages III and IV)

  • Primary Drugs:

    • Combination chemotherapy:

      •  vinblastine (Velban)

      •  doxorubicin (Adriamycin)

      •  dacarbazine (DTIC)

      •  bleomycin (Blenoxane)

  • Other useful drugs/modalities:

• Non-Hodgkin's lymphoma:

  • Primary drugs:

    • Combination therapy:

      •  cyclophosphamide (Cytoxan)

      •  doxorubicin (Adriamycin)

      •  vincristine (Oncovin)

      •   prednisone (Deltasone)

    • Other useful drugs/modalities:

      • Stem cells transplantation

      • monoclonal antibody treatment (investigational)

      • Cytokine therapy (interleukin 12) (investigational)

      • vaccination

• Multiple Myeloma:

  • Primary drugs:

    •  melphalan (Alkeran)plus prednisone (Deltasone)

    • Combination therapy

  • Other useful drugs/modalities:

    • cyclophosphamide (Cytoxan)

    • vincristine (Oncovin)

    • carmustine (BNCU,BiCNU)

    • interferon

    • doxorubicin (Adriamycin)

• Chronic lymphocytic leukemia

  • Primary drugs:

    • chlorambucil (Leukeran) and prednisone (Deltasone)(if indicated)

    • fludarabine (Fludara)

  • Other useful drug/modalities:

    • chlorambucil (Leukeran) and prednisone (Deltasone)

    • allopurinol (Zyloprim, Purinol)-- supportive agent; xanthine oxidase inhibitor (reduces hyperuricemia)

    • doxorubicin (Adriamycin)

    • cladribine (Leustatin)

• Chronic myelogenous leukemia

  • Primary drugs:

    • busulfan (Myleran) or interferon

    • allogenic bone marrow transplantation (certain patients)

  • Other useful drugs/modalities:

    • vincristine (Oncovin)

    • mercaptopurine (Purinethol)

    • hydroxyurea (Hydrea)

    • melphalan (Alkeran)

    • interferon

    • allopurinol (Zyloprim, Purinol)-- supportive agent; xanthine oxidase inhibitor (reduces hyperuricemia)

• Acute myelocytic and myelomonocytic leukemia:

  • Primary drugs:

    •  Combination Therapy:cytarabine (ARA-C) and

      •  mitoxantrone (Novantrone) or

      •  daunorubicin (DaunoXome) or

      •  idarubicin (Idamycin)

  • Other useful drugs/modalities:

    •  methotrexate

    • thioguanine

    • mercaptopurine (Purinethol)

    • allopurinol (Zyloprim, Purinol) -- supportive agent; xanthine oxidase inhibitor (reduces hyperuricemia)

    • mitoxantrone (Novantrone)

    • etoposide (VP-16,VePe-sid)

    • asacitidine (investigational)

    • amsacrine (investigational)

• Lung carcinoma:

  • Primary drugs:

    • etoposide (VP-16,VePe-sid) plus cisplatin (Platinol), vinorelbine (Navelbine)

  • Other useful drugs/modalities:

    • methotrexate

    • vincristine (Oncovin)

    • vinblastine (Velban)

    • doxorubicin (Adriamycin)

    • mitomycin (Mutamycin)

• Head and Neck carcinoma:

  • Primary drugs:

    • fluorouracil (5-FU) plus cisplatin (Platinol)

  • Other useful drugs/modalities:

    • methotrexate

    • bleomycin (Blenoxane)

    • hydroxyurea (Hydrea)

    • daunorubicin (DaunoXome)

    • vincristine (Oncovin)

    • vinorelbine (Navelbine)

Salmon, S. E. and Sartorelli, A. C. Cancer Chemotherapy, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 903-904 (adapted from table 55-7)